Navigation Links
In New Study, Duloxetine Reduced Non-specific Pain and Emotional,Symptoms Associated with Depression

MADRID, Spain, 19 march 2007 - The antidepressant duloxetine, at a once-daily dose of 60 mg, significantly reduced non-specific pain and emotional symptoms associated with depression in a new, eight-week, placebo-controlled study of 327 adult patients with at least moderate pain and major depression. The results were presented today at the 15th European Congress of Psychiatry (AEP) in Madrid, Spain.

Duloxetine, a member of a class of drugs commonly referred to as serotonin and norepinephrine reuptake inhibitors (SNRIs), is approved in more than 70 countries for the treatment of major depression.

“Whereas traditionally, the focus has been on treating only emotional symptoms of depression, we now know that the presence of physical symptoms, specifically pain, can obscure the diagnosis and complicate the management of patients,” said Professor Koen Demyttenaere, Department of Psychiatry at University Hospital Gasthuisberg in Belgium and lead study investigator. “In this study of depressed patients with at least moderate pain, duloxetine helped by significantly reducing both painful and emotional symptoms of depression, and in decreasing the interference of pain with functioning.”

In the study:
Average pain scores, the primary outcome measured, decreased significantly among patients treated with duloxetine by 45 percent (on an 11-point Likert scale from 5.7 at baseline to 3.13 at the final visit in Week 8) compared with a decrease of 29 percent (from 5.7 to 4.06) among those taking placebo (p< 0.001).
Duloxetine significantly reduced core emotional symptoms, as assessed by the Montgomery-Asberg Depression Rating Scale (MADRS), by 56 percent (from an average score of 29.6 at baseline to 12.91 at Week 8), compared with a 39-percent reduction (from 29.6 to 18.29) in patients taking placebo (p<0.0001).
53 percent of duloxetine-treated patients reached remis
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. In New Study, Duloxetine Was Equally Effective, Regardless of Switch Method, in Reducing Painful Symptoms in Ssri Non- or Partial-responders with Depression
2. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
7. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
8. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
9. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
10. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
11. Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos Bevirimat
Post Your Comments:
(Date:4/27/2015)... 27, 2015 Bronstein, Gewirtz & Grossman, LLC ... the securities of Celladon Corporation ("Celladon" or the "Company") ... Peretz Bronstein or his investor relations coordinator ... 212-697-6484. The investigation concerns whether Celladon and ... 10(b) and 20(a) of the Securities Exchange Act of ...
(Date:4/27/2015)... 27, 2015 Vermillion, Inc. (VRML), ... disease, announced today it will report first ... close on Monday, May 11, 2015, followed ... at 4:30pm Eastern.Conference Call & Webcast: Monday, ... Domestic: , 888-556-4997International: , 719-457-2628Conference ID: , ...
(Date:4/27/2015)... , April 27, 2015  Novira Therapeutics, Inc., a ... curative treatment of chronic hepatitis B virus (HBV) infection, ... its lead HBV core inhibitor candidate, NVR 3-778, at ... the Study of the Liver (EASL) in ... of NVR 3-778 from studies performed in a humanized ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Celladon Corporation 2Novira Therapeutics Announces Presentation of Preclinical Antiviral Data for NVR 3-778 at EASL 2Novira Therapeutics Announces Presentation of Preclinical Antiviral Data for NVR 3-778 at EASL 3
... 2011 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... and commercialization of products for central nervous system disorders, ... one of Israel,s leading private biotech, pharmaceutical and medical ... Israel. "We are excited to reach this ...
... Cell Therapeutics, Inc. ("CTI") (NASDAQ: CTIC ... that final results from the phase II OPAL study ... acute myeloid leukemia (AML) were presented by Jorge Cortes, ... Center during the Acute Myeloid Leukemia - Therapy, excluding ...
Cached Medicine Technology:Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel 2Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel 3Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel 4Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 2Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 3Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 4
(Date:4/27/2015)... As ISO 27001 has quickly become ... of all sizes and in all industries, Pivot Point ... for ISO 27001 certification. The information security audit firm ... for ISO 27001 certification. Pivot Point's commitment to ISO ... number of Lead Implementers and Auditors the company employs ...
(Date:4/27/2015)... Guided by the extensive work of its community ... collaboration with organizations around the world to identify proven ... essential actions for organizations committed to patient experience ... systems committed to providing the best in experience will:, ... with committed time and focused intent to shape and ...
(Date:4/27/2015)... PHILADELPHIA, PA (PRWEB) April 27, 2015 ... it will exhibit its wide range of market leading ... to May 7 in Geneva, Switzerland. Vitafoods Europe 2015 ... over 100 countries showcasing the latest research in such ... personalized nutrition. , FMC Health and Nutrition’s booth ...
(Date:4/27/2015)... On May 15, Mount Soma Ashram ... campaign to raise awareness of the vision of Mount ... Somesvara Temple. Ironically, when many of these people moved ... thought they were leaving the social and technological world ... of meditation, service to a higher cause, deep introspection, ...
(Date:4/27/2015)... York, NY (PRWEB) April 27, 2015 ... are creating a seamless referral process for the Health ... with chronic heart failure or diabetes, for instance, may ... most primary physicians coordinate with many other care providers. ... referring hundreds of thousands of patients each year, the ...
Breaking Medicine News(10 mins):Health News:Six Additional New ISO 27001 Lead Implementers Certified for Pivot Point Security 2Health News:Guiding Principles for Patient Experience Excellence Identified by The Beryl Institute 2Health News:FMC Health and Nutrition to Feature Epax® Brand Omega-3 Ingredients at Vitafoods Europe 2015 2Health News:Mount Soma Monks Do Social Media 2Health News:Mount Sinai Launches System for Faster Referrals 2Health News:Mount Sinai Launches System for Faster Referrals 3
... American Institute of Ultrasound in Medicine (AIUM) and ... the collaborative development of the Practice Guideline for ... Practice of Urology. This guideline has been developed ... the practice of urology and provides direction in ...
... Molecular Medicine (MDC) Berlin-Buch have found out why the ... the world,s most unusual mammals, feels no pain when ... in narrow dark burrows where ambient carbon dioxide (CO2) ... converted into acid, which continuously activates pain sensors. However, ...
... , TUESDAY, Dec. 20 (HealthDay News) -- Increased public ... reasons why child and teen exposure to unwanted online ... States, a new study indicates. However, reports of ... University of New Hampshire Crimes Against Children Research Center. ...
... "disarray and dysfunction" jeopardize access to medical care ... military families, said the American College of Physicians ... with House and Senate leadership. ACP is ... membership organizationin the United States, representing 132,000 internal ...
... A hike in your blood pressure during middle age significantly ... stroke during your lifetime, according to new Northwestern Medicine research. ... maintaining low blood pressure early in middle age to prevent ... developed high blood pressure in middle age or who started ...
... evaluating early kidney injuries in people, doctors monitor blood ... breakdown, to understand the severity of the injury. Creatinine ... an indication of early damage to vital kidney function. ... Missouri researchers have found that even tiny increases of ...
Cached Medicine News:Health News:MDC researchers: Ion channel makes African naked mole-rat insensitive to acid-induced pain 2Health News:MDC researchers: Ion channel makes African naked mole-rat insensitive to acid-induced pain 3Health News:Youth Exposure to Unwanted Internet Sexual Encounters Drops 2Health News:Congress' 'disarray' makes it 'likely' that 27 percent Medicare cut will go in effect 2Health News:New predictor of heart attack or stroke 2Health News:MU researchers find pet kidney injuries are similar to human kidney injuries 2
... patented ratchet design provides fingertip ratchet disengagement ... I Instrument program offers state-of-the-art quality in ... maintaining strength and durability. Low profile cutting ... joint spaces. Series I instruments are available ...
... ratchet design provides fingertip ratchet disengagement allowing ... Instrument program offers state-of-the-art quality in an ... strength and durability. Low profile cutting tips ... spaces. Series I instruments are available in ...
... patented ratchet design provides fingertip ratchet disengagement ... I Instrument program offers state-of-the-art quality in ... maintaining strength and durability. Low profile cutting ... joint spaces. Series I instruments are available ...
... A broad selection of procedurally specific ... and allow easy access to all ... variety of approaches.,Loop Handled Graspers feature ... holds tissue firmly without tearing or ...
Medicine Products: